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Dilyse Nuttall 
 
Calculation Skills: Menopause & Hormone Replacement Therapy 
National Institute of Health and Care Excellence [NICE] are currently developing guidelines 
on the diagnosis and management of menopause and these are due for release in October 
2015. This is a welcome development which acknowledges the significant impact that the 
symptoms related to the menopause can have on the individual. NICE (2013) identify 
menopause as the ending of menstruation resulting from a failure in ovarian follicular activity. 
The changes in hormone levels commonly cause uncomfortable symptoms which include hot 
flushes; night sweats; dyspareunia; vaginal dryness and discomfort and disturbed sleep 
(NICE, 2013). The average woman’s age at menopause is 52 years. According to NICE 
(2013), 80% of women will endure the symptoms of menopause and 45% of those would 
consider the symptoms to be distressing. 
 
 
Question 1 
  
Mary works in a large organisation where 65% of the 400 staff are female. Based on the NICE 
(2013) estimates, identify how many women (rounded up or down to nearest whole number) 
in Mary’s organisation are likely to experience distressing menopausal symptoms. 
 
 
Question 2 
 
Although some women are able to manage the symptoms with lifestyle changes, it is 
recognised that some women benefit from the use of hormone replacement therapy to manage 
their distressing symptoms. However, HRT is not without risk and so the benefits should be 
considered alongside the risks to the individual woman (JFC, 2014). Risk can be reduced by 
prescribing the minimum effective dose for the shortest period (JFC, 2014). Table 1 highlights 
some of the risks associated with HRT use (JFC, 2014). 
 
Table 1 Source JFC (2014) 
RISK Age range Incidence per 
1000 women not 
using HRT 
(over 5 yrs) 
Additional 
cases per 1000 
women using 
Oestrogen only 
HRT 
(for 5 yrs use) 
Additional 
cases per 1000 
women using 
combined HRT 
(for 5yrs use) 
Breast Cancer 50-59 
60-69 
10 
15 
2 
3 
6 
9 
Venous 
thromboembolism 
50-59 
60-69 
5 
8 
2 
2 
7 
10 
Stroke 50-59 
60-69 
4 
9 
1 
3 
1 
3 
 
(i) How many women 60-69, out of a population of 5000, who are not using HRT, would 
experience breast cancer? 
 
(ii) In a population of 20,000 women using oestrogen only HRT, spanning the age range of 
50-69, how many additional cases of venous thromboembolism would be expected?  
 
(iii) How much higher (expressed as a fraction) is the incidence of stroke in 60-69 year old 
women using combined HRT for 5 years? 
 
(iv) Expressed as a percentage, how many more cases of breast cancer are there with 
combined HRT use, than non-HRT use (in the 50-59 years age group)? 
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Question 3 
 
Mary is prescribed low dose conjugated oestrogens with progestogen for her menopausal 
symptoms. Each tablet contains 300 micrograms of oestrogen and 1.5mg of 
medroxyprogesterone. She is to take 1 tablet per day. The tablets are available as 28-tablet 
packs, at a cost of £6.52 for three packs. 
 
(i) How many packs (without splitting packs) will Mary need in order to take the HRT for a full 
year? 
 
(ii) If Mary takes this treatment for a full year, how much oestrogen will she have received 
during this period (expressed as mg)? 
 
(iii) How much medroxyprogesterone will Mary have received in a year? 
 
(iv) What is the daily cost of this treatment (rounded up or down to nearest pence)? 
 
 
 
Answers 
 
Question 1 
 
Number of staff in organisation (100%) = 400 
Number of women (65%) = 400 ÷ 100 x 65 = 260 
 
Number of women who will experience symptoms (80%) = 260 ÷ 100 x 80 = 208 
Number of women who will experience distressing symptoms (40% of those with symptoms) 
= 208 ÷ 100 x 45 = 94 
 
Answer: 94 (rounded up). 
 
 
Question 2 
 
(i) Incidence 15 / 1000. Population of 5000: 15 x 5 = 75 
 
(ii) Additional cases 50-59 = 2/1000, Additional cases 60-69 = 2/1000. Total additional cases 
= 4 /1000. In a population of 20,000 = 4 x 20 = 80 additional cases. 
 
(iii) Incidence in women not using HRT = 9 women 
      Additional cases in women using combined HRT = 3 
      9 ÷ 3 = 3 
      The incidence is a 3rd higher 
 
(iv) Non HRT = 10 women per 1000 
Combined HRT = 6 additional women per 1000 
60% more women 
 
Question 3 
(i) 1 year = 365 days. 1 pack = 28 tablets. Dose = 1 tablet per day. 
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    365 ÷ 28 = 13.04 
    Will need 14 packs 
 
(ii) 365 x 300 = 109500 micrograms 
     Expressed as mg = 109.5 mg 
 
(iii) 1 tablet contains 1.5mg. 365 x 1.5 = 547.5 mg 
 
(iv) 3 packs (total 84 tablets) = £6.52 or 652p 
 
652 ÷ 84 = 7.76p 
 
Rounded up = 8p 
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